Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: Systematic review and economic evaluation

Health Technology Assessment

Volumn 18, Issue 56, 2014, Pages 1-559

  Colquitt, Jill L ^a   Mendes, Diana ^a   Clegg, Andrew J ^a   Harris, Petra ^a   Cooper, Keith ^a   Picot, Joanna ^a   Bryant, Jackie ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENOXIMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METOPROLOL; MILRINONE; NITRIC ACID DERIVATIVE; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; SOTALOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; WARFARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATAXIA; ATHEROGENESIS; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BRADYCARDIA; BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVERSION; CLINICAL EFFECTIVENESS; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DEVICE INFECTION; DIABETES MELLITUS; DISEASE DURATION; DISTRESS SYNDROME; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ELECTROCARDIOGRAPHY; ELECTRODE; FAINTNESS; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HEMATOMA; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INSOMNIA; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIFESTYLE; LIVER TOXICITY; LONGEVITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; OBESITY; PAIN; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY DISORDER; PHYSICAL MOBILITY; PLEURA EFFUSION; PNEUMOTHORAX; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROGNOSIS; PSYCHOLOGICAL WELL BEING; QRS COMPLEX; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SCINTIANGIOGRAPHY; SECONDARY PREVENTION; SEROMA; SINUS RHYTHM; SKIN DISCOLORATION; SLEEP DISORDER; SOCIAL ISOLATION; SOCIAL STATUS; SUDDEN CARDIAC DEATH; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TACHYCARDIA; THYROID DISEASE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREMOR; UNSPECIFIED SIDE EFFECT; VEIN PERFORATION; VERY ELDERLY; VISUAL DISORDER; ARRHYTHMIAS, CARDIAC; COST BENEFIT ANALYSIS; DEVICES; ECONOMICS; HEALTH CARE COST; STATISTICS AND NUMERICAL DATA;

ARRHYTHMIAS, CARDIAC; CARDIAC RESYNCHRONIZATION THERAPY; COST-BENEFIT ANALYSIS; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HEALTH CARE COSTS; HEART FAILURE; HUMANS;

EID: 84907375291     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18560     Document Type: Article

References (244)

1. National Institute for Health and Clinical Excellence. Implantable Cardioverter Defibrillators for the Treatment of Arrhythmias and Cardiac Resynchronisation Therapy for the Treatment of Heart Failure (Review of TA95 and TA120). Final Scope. London: NICE; 2011.
2. Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine. Philadelphia, PA: Elsevier Saunders; 2012.
3. Chugh S, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008; 51: 213-28. http://dx. doi. org/10. 1016/j. pcad. 2008. 06. 003.
4. Office for National Statistics. Deaths Registered in England and Wales in 2010 by Cause. Statistical Bulletin. 28 October 2011. URL: www. ons. gov. uk/ons/dcp171778_239518. pdf (accessed 23 January 2014).
5. World Health Organization. International Classification of Diseases, 10th Edition. URL: www. who. int/classifications/icd/en/(accessed April 2014).
6. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation 2012; 125: 1043-52. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 111. 023846.
7. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48: e247-346. http://dx. doi. org/10. 1016/j. jacc. 2006. 07. 010.
8. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 1996; 93: 519-24. http://dx. doi. org/10. 1161/01. CIR. 93. 3. 519.
9. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008; 118: 1497-518. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 107. 189375.
10. Lopshire JC, Zipes DP. Sudden cardiac death: better understanding of risks, mechanisms, and treatment. Circulation 2006; 114: 1134-6. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 106. 647933.
11. Youngquist ST, Kaji AH, Niemann JT. Beta-blocker use and the changing epidemiology of out-of-hospital cardiac arrest rhythms. Resuscitation 2008; 76: 376-80. http://dx. doi. org/10. 1016/j. resuscitation. 2007. 08. 022.
12. Polentini MS, Pirrallo RG, McGill W. The changing incidence of ventricular fibrillation in Milwaukee, Wisconsin (1992-2002). Prehosp Emerg Care 2006; 10: 52-60. http://dx. doi. org/10. 1080/10903120500366961.
13. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 2002; 288: 3008-13. http://dx. doi. org/10. 1001/jama. 288. 23. 3008.
14. Bunch TJ, White RD. Trends in treated ventricular fibrillation in out-of-hospital cardiac arrest: ischemic compared to non-ischemic heart disease. Resuscitation 2005; 67: 51-4. http://dx. doi. org/10. 1016/j. resuscitation. 2005. 04. 015.
15. Berdowski J, Berg RA, Tijssen JG, Koster RW. Global incidences of out-of-hospital cardiac arrest and survival rates: systematic review of 67 prospective studies. Resuscitation 2010; 81: 1479-87. http://dx. doi. org/10. 1016/j. resuscitation. 2010. 08. 006.
16. Bunch TJ, Kottke TE, Lopez-Jimenez F, Mahapatra S, Elesber AA, White RD. A comparative analysis of short-and long-term outcomes after ventricular fibrillation out-of-hospital cardiac arrest in patients with ischemic and nonischemic heart disease. Am J Cardiol 2006; 98: 857-60. http://dx. doi. org/10. 1016/j. amjcard. 2006. 04. 023.
17. Dumas F, Rea TD. Long-term prognosis following resuscitation from out-of-hospital cardiac arrest: role of aetiology and presenting arrest rhythm. Resuscitation 2012; 83: 1001-5. http://dx. doi. org/10. 1016/j. resuscitation. 2012. 01. 029.
18. Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP, et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation 2011; 123: 2423-30. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 110. 959734.
19. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-46. http://dx. doi. org/10. 1136/hrt. 2003. 025270.
20. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999; 20: 421-8. http://dx. doi. org/10. 1053/euhj. 1998. 1280.
21. Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001; 22: 228-36. http://dx. doi. org/10. 1053/euhj. 2000. 2289.
22. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007; 28: 1128-34. http://dx. doi. org/10. 1093/eurheartj/ehm102.
23. Taylor CJ, Roalfe AK, Iles R, Hobbs FD. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur J Heart Fail 2012; 14: 176-84. http://dx. doi. org/10. 1093/eurjhf/hfr170.
24. Madsen BK, Hansen JF, Stokholm KH, Brons J, Husum D, Mortensen LS. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J 1994; 15: 303-10.
25. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 2003; 89: 605-9. http://dx. doi. org/10. 1136/heart. 89. 6. 605.
26. Ahmed A, Aronow WS, Fleg JL. Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. Am J Ther 2006; 13: 325-31. http://dx. doi. org/10. 1097/00045391-200607000-00009.
27. Holland R, Rechel B, Stepien K, Harvey I, Brooksby I. Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail 2010; 16: 150-6. http://dx. doi. org/10. 1016/j. cardfail. 2009. 08. 010.
28. Miller-Davis C, Marden S, Leidy NK. The New York Heart Association classes and functional status: what are we really measuring? Heart Lung 2006; 35: 217-24. http://dx. doi. org/10. 1016/j. hrtlng. 2006. 01. 003.
29. Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary heart disease statistics: heart failure supplement. London: British Heart Foundation; 2010. URL: www. bhf. org. uk/research/statistics. aspx (accessed 11 May 2012).
30. Boehmer JP. CRT only or CRT plus ICD? Eur Heart J 2004; 6: D83-7. http://dx. doi. org/10. 1016/j. ehjsup. 2004. 05. 003.
31. Schaer BA, Koller MT, Sticherling C, Altmann D, Joerg L, Osswald S. Longevity of implantable cardioverter-defibrillators, influencing factors, and comparison to industry-projected longevity. Heart Rhythm 2009; 6: 1737-43. http://dx. doi. org/10. 1016/j. hrthm. 2009. 09. 013.
32. Horlbeck FW, Mellert F, Kreuz J, Nickenig G, Schwab JO. Real-world data on the lifespan of implantable cardioverter-defibrillators depending on manufacturers and the amount of ventricular pacing. J Cardiovasc Electrophysiol 2012; 23: 1336-42. http://dx. doi. org/10. 1111/j. 1540-8167. 2012. 02408. x.
33. Hauser R, Hayes D, Parsonnet V, Furman S, Epstein A, Hayes J, et al. Feasibility and initial results of an internet-based pacemaker and ICD pulse generator and lead registry. Pacing Clin Electrophysiol 2001; 24: 82-7. http://dx. doi. org/10. 1046/j. 1460-9592. 2001. 00082. x.
34. Olde NLR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS, et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J 2012; 163: 753-60. http://dx. doi. org/10. 1016/j. ahj. 2012. 02. 012.
35. Pedersen SS, Lambiase P, Boersma LV, Murgatroyd F, Johansen JB, Reeve H, et al. Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD: design and rationale of the EFFORTLESS S-ICD Registry. Pacing Clin Electrophysiol 2012; 35: 574-9. http://dx. doi. org/10. 1111/j. 1540-8159. 2012. 03337. x.
36. Gras D, Bocker D, Lunati M, Wellens HJ, Calvert M, Freemantle N, et al. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace 2007; 9: 516-22. http://dx. doi. org/10. 1093/europace/eum080.
37. Biffi M, Moschini C, Bertini M, Saporito D, Ziacchi M, Diemberger I, et al. Phrenic stimulation: a challenge for cardiac resynchronization therapy. Circ Arrhythm Electrophysiol 2009; 2: 402-10. http://dx. doi. org/10. 1161/CIRCEP. 108. 836254.
38. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 2011; 58: 995-1000. http://dx. doi. org/10. 1016/j. jacc. 2011. 06. 007.
39. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Am Coll Cardiol 2011; 58: 1007-13. http://dx. doi. org/10. 1016/j. jacc. 2011. 04. 039.
40. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States. J Am Coll Cardiol 2011; 58: 1001-6. http://dx. doi. org/10. 1016/j. jacc. 2011. 04. 033.
41. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Europace 2008; 10: 707-25. http://dx. doi. org/10. 1093/europace/eun122.
42. National Institute for Health and Clinical Excellence. Implantable Cardioverter Defibrillators for Arrhythmias (TA95). London: NICE; 2006.
43. National Institute for Health and Clinical Excellence. Cardiac Resynchronisation Therapy for the Treatment of Heart Failure (TA120). London: NICE; 2007.
44. National Institute for Health and Clinical Excellence. Chronic Heart Failure: Management of Chronic Heart Failure in Adults in Primary and Secondary Care. NICE clinical guidelines CG108, August 2010. URL: http://publications. nice. org. uk/chronic-heart-failure-cg108 (accessed 23 January 2014).
45. Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Guidelines for cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2007; 28: 2256-95. http://dx. doi. org/10. 1093/eurheartj/ehm305.
46. Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America guideline committee. J Card Fail 2012; 18: 94-106. http://dx. doi. org/10. 1016/j. cardfail. 2011. 12. 004.
47. Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NAM, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 1297-313. http://dx. doi. org/10. 1016/j. jacc. 2012. 07. 009.
48. Department of Health. Coronary Heart Disease: National Service Framework for Coronary Heart Disease-Modern Standards and Service Models. London: Department of Health; 2000.
49. Heart Rhythm UK. Standards for Implantation and Follow-Up of Cardiac Rhythm Management Devices. Heart Rhythm UK; 2011.
50. Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30: 1245-53. http://dx. doi. org/10. 1093/eurheartj/ehp100.
51. Lane RE, Cowie MR, Chow AWC. Prediction and prevention of sudden cardiac death in heart failure. Heart 2005; 91: 674-80. http://dx. doi. org/10. 1136/hrt. 2003. 025254.
52. National Institute for Health and Clinical Excellence. NICE Pathway: Chronic Heart Failure. London: NICE; 2010.
53. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-847. http://dx. doi. org/10. 1093/eurheartj/ehs104.
54. National Institute for Health and Clinical Excellence. Short-Term Circulatory Support with Left Ventricular Assist Devices as a Bridge to Cardiac Transplantation or Recovery. London: NICE; 2006.
55. Cunningham D, Charles R, Cunningham M, de Lange A. Cardiac Rhythm Management: UK National Clinical Audit 2010. London: National Institute for Cardiovascular Outcomes Research; 2012.
56. Cunningham D, Charles R, Cunningham M, Whittaker T. Cardiac Rhythm Management: UK National Clinical Audit Report. London: National Institute for Cardiovascular Outcomes Research; 2012.
57. Scott PA, Turner NG, Chung A, Morgan JM, Roberts PR. Varying implantable cardioverter defibrillator referral patterns from implanting and non-implanting hospitals. Europace 2009; 11: 1048-51. http://dx. doi. org/10. 1093/europace/eup145.
58. McDonagh T, Standing M, Cleland J, Mitchell P, Dargie H, Cunningham D, et al. National Heart Failure Audit April 2010-March 2011. London: National Institute for Cardiovascular Outcomes Research; 2012.
59. Scott PA, Whittaker A, Zeb M, Watts E, Yue AM, Roberts PR, et al. Rates of upgrade of ICD recipients to CRT in clinical practice and the potential impact of the more liberal use of CRT at initial implant. Pacing Clin Electrophysiol 2012; 35: 73-80. http://dx. doi. org/10. 1111/j. 1540-8159. 2011. 03255. x.
60. Camm JA, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the 'enigma'? Europace 2010; 12: 1063-9. http://dx. doi. org/10. 1093/europace/euq282.
61. National Institute for Health and Care Excellence. Arrhythmias-ICDs & Heart Failure-Cardiac Resynchronisation: Final Scope. URL: www. nice. org. uk/guidance/ta314/resources/arrythmias-icds-heart-failure-cardiac-resynchronisation-final-scope2 (accessed 19 September 2012).
62. Bryant J, Brodin H, Loveman E, Payne E, Clegg A. The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review. Health Technol Assess 2005; 9(36).
63. Parkes J, Bryant J, Milne R. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review. Health Technol Assess 2000; 4(26).
64. Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess 2007; 11(47).
65. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 (updated March 2011). The Cochrane Collaboration, 2011. URL: www. cochrane-handbook. org (accessed February 2014).
66. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83. http://dx. doi. org/10. 1136/bmj. 313. 7052. 275.
67. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal, 2013. London: NICE; 2013.
68. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8(36).
69. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-12. http://dx. doi. org/10. 1016/S0735-1097(03)00297-3.
70. Wijetunga M, Strickberger SA; Amiodarone Versus Implantable Defibrillator Randomized Trial. Amiodarone versus Implantable Defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications. Card Electrophysiol Rev 2003; 7: 452-6. http://dx. doi. org/10. 1023/B: CEPR. 0000023158. 52511. 76.
71. AVID investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-83. http://dx. doi. org/10. 1056/NEJM199711273372202.
72. AVID investigators. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999; 34: 1552-9. http://dx. doi. org/10. 1016/S0735-1097 (99)00376-9.
73. Hallstrom AP. Antiarrhythmics Versus Implantable Defibrillators (AVID)-rationale, design, and methods. Am J Cardiol 1995; 75: 470-5. http://dx. doi. org/10. 1016/S0002-9149(99)80583-9.
74. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002; 105: 589-94. http://dx. doi. org/10. 1161/hc0502. 103330.
75. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch trial investigators. N Engl J Med 1997; 337: 1569-75. http://dx. doi. org/10. 1056/NEJM199711273372201.
76. The Coronary Artery Bypass Graft (CABG) Patch trial. The CABG Patch trial investigators and coordinators. Prog Cardiovasc Dis 1993; 36: 97-114.
77. Bigger JT Jr, Parides MK, Rolnitzky LM, Meier P, Levin B, Egan DA. Changes in sample size and length of follow-up to maintain power in the Coronary Artery Bypass Graft (CABG) Patch trial. Control Clin Trials 1998; 19: 1-14. http://dx. doi. org/10. 1016/S0197-2456(97)00124-4.
78. Bigger JT, Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB, et al. Mechanisms of death in the CABG Patch trial-a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999; 99: 1416-21. http://dx. doi. org/10. 1161/01. CIR. 99. 11. 1416.
79. Spotnitz HM, Herre JM, Raza ST, Hammon JW Jr, Baker LD Jr, Fitzgerald DM, et al. Effect of implantable cardioverter-defibrillator implantation on surgical morbidity in the CABG Patch trial. Surgical investigators of the Coronary Artery Bypass Graft Patch trial. Circulation 1998; 98(Suppl. 19): II77-80.
80. Namerow PB, Firth BR, Heywood GM, Windle JR, Parides MK. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch trial. Pacing Clin Electrophysiol 1999; 22: 1305-13. http://dx. doi. org/10. 1111/j. 1540-8159. 1999. tb00623. x.
81. Kuck K-H, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-54. http://dx. doi. org/10. 1161/01. CIR. 102. 7. 748.
82. Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453-8. http://dx. doi. org/10. 1161/01. CIR. 0000012350. 99718. AD.
83. German Dilated Cardiomyopathy Study investigators. Prospective studies assessing prophylactic therapy in high risk patients: the German Dilated CardioMyopathy Study (GDCMS)-study design. Pacing Clin Electrophysiol 1992; 15: 697-700. http://dx. doi. org/10. 1111/j. 1540-8159. 1992. tb05166. x.
84. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-302. http://dx. doi. org/10. 1161/01. CIR. 101. 11. 1297.
85. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, et al. Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators. Am J Cardiol 1993; 72: 103-8F. http://dx. doi. org/10. 1016/0002-9149(93)90972-F.
86. Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation 2000; 101: 1660-4. http://dx. doi. org/10. 1161/01. CIR. 101. 14. 1660.
87. Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002; 144: 282-9. http://dx. doi. org/10. 1067/mhj. 2002. 124049.
88. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004; 110: 112-16. http://dx. doi. org/10. 1161/01. CIR. 0000134957. 51747. 6E.
89. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R, Bhuripanyo K, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107: 2221-6. http://dx. doi. org/10. 1161/01. CIR. 0000066319. 56234. C8.
90. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8. http://dx. doi. org/10. 1056/NEJMoa033088.
91. Kadish A, Quigg R, Schaechter A, Anderson KP, Estes M, Levine J. Defibrillators in nonischemic cardiomyopathy treatment evaluation. Pacing Clin Electrophysiol 2000; 23: 338-43. http://dx. doi. org/10. 1111/j. 1540-8159. 2000. tb06759. x.
92. Schaechter A, Kadish AH; DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation. DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). Card Electrophysiol Rev 2003; 7: 457-62. http://dx. doi. org/10. 1023/B: CEPR. 0000023162. 45506. c4.
93. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006; 113: 776-82. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 105. 561571.
94. Passman R, Subacius H, Ruo B, Schaechter A, Howard A, Sears SF, et al. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med 2007; 167: 2226-32. http://dx. doi. org/10. 1001/archinte. 167. 20. 2226.
95. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-8. http://dx. doi. org/10. 1056/NEJMoa041489.
96. Hohnloser SH, Connolly SJ, Kuck KH, Dorian P, Fain E, Hampton JR, et al. The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): study protocol. Am Heart J 2000; 140: 735-9. http://dx. doi. org/10. 1067/mhj. 2000. 110088.
97. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361: 1427-36. http://dx. doi. org/10. 1056/NEJMoa0901889.
98. Steinbeck G, Andresen D, Senges J, Hoffmann E, Seidl K, Brachmann J, et al. Immediate Risk-Stratification Improves Survival (IRIS): study protocol. Europace 2004; 6: 392-9. http://dx. doi. org/10. 1016/j. eupc. 2004. 04. 008.
99. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation trial investigators. N Engl J Med 1996; 335: 1933-40. http://dx. doi. org/10. 1056/NEJM199612263352601.
100. MADIT Executive Committee. Multicenter Automatic Defibrillator Implantation Trial (MADIT): design and clinical protocol. MADIT Executive Committee. Pacing Clin Electrophysiol 1991; 14: 920-7. http://dx. doi. org/10. 1111/j. 1540-8159. 1991. tb04136. x.
101. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83. http://dx. doi. org/10. 1056/NEJMoa013474.
102. Moss AJ, Cannom DS, Daubert JP, Hall WJ, Higgins SL, Klein H, et al. Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): design and clinical protocol. Ann Noninvasive Electrocardiol 1999; 4: 83-91. http://dx. doi. org/10. 1111/j. 1542-474X. 1999. tb00369. x.
103. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43: 1459-65. http://dx. doi. org/10. 1016/j. jacc. 2003. 11. 038.
104. Noyes K, Corona E, Zwanziger J, Hall J, Zhao HW, Wang HK, et al. Health-related quality of life consequences of implantable cardioverter defibrillators-results from MADIT II. Med Care 2007; 45: 377-85. http://dx. doi. org/10. 1097/01. mlr. 0000257142. 12600. c1.
105. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37. [Erratum published in N Engl J Med 2005; 352: 2146.] http://dx. doi. org/10. 1056/NEJMoa043399.
106. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Poole JE, Lee KL, et al. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2008; 155: 501-6. http://dx. doi. org/10. 1016/j. ahj. 2007. 10. 022.
107. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L, et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008; 359: 999-1008. http://dx. doi. org/10. 1056/NEJMoa0706719.
108. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 2009; 120: 2170-6. [Erratum published in Circulation 2010; 121: e39.] http://dx. doi. org/10. 1161/CIRCULATIONAHA. 109. 853689.
109. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49. http://dx. doi. org/10. 1056/NEJMoa050496.
110. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001; 3: 481-9. http://dx. doi. org/10. 1016/S1388-9842(01)00176-3.
111. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928-32. http://dx. doi. org/10. 1093/eurheartj/ehl099.
112. Cleland J, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response: a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. J Am Coll Cardiol 2008; 52: 438-45. http://dx. doi. org/10. 1016/j. jacc. 2008. 04. 036.
113. Cleland JG, Calvert MJ, Verboven Y, Freemantle N. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J 2009; 157: 457-66. http://dx. doi. org/10. 1016/j. ahj. 2008. 11. 006.
114. Gervais R, Leclercq C, Shankar A, Jacobs S, Eiskjaer H, Johannessen A, et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail 2009; 11: 699-705. http://dx. doi. org/10. 1093/eurjhf/hfp074.
115. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2009; 11: 480-8. http://dx. doi. org/10. 1093/eurjhf/hfp034.
116. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50. http://dx. doi. org/10. 1056/NEJMoa032423.
117. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 2000; 6: 276-85. http://dx. doi. org/10. 1054/jcaf. 2000. 9501.
118. US Food and Drug Administration. Summary of Safety and Effectiveness Data. P010012/SO26. Washington, DC: US Food and Drug Administration; 2004.
119. Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2329-34. [Erratum appears in J Am Coll Cardiol 2008; 51: 2197.] http://dx. doi. org/10. 1016/j. jacc. 2005. 09. 016.
120. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation 2009; 119: 969-77. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 108. 793273.
121. Abraham WT, Fisher WG, Smith AL, DeLurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-53. http://dx. doi. org/10. 1056/NEJMoa013168.
122. Abraham WT. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). J Card Fail 2000; 6: 369-80. http://dx. doi. org/10. 1054/jcaf. 2000. 20841.
123. US Food and Drug Administration. Summary of Safety and Effectiveness. P010015. Washington, DC: US Food and Drug Administration; 2001.
124. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107: 1985-90. http://dx. doi. org/10. 1161/01. CIR. 0000065226. 24159. E9.
125. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-80. http://dx. doi. org/10. 1056/NEJM200103223441202.
126. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454-9. http://dx. doi. org/10. 1016/S0735-1097(03)01042-8.
127. Saxon LA, Boehmer JP, Hummel J, Kacet S, De Marco T, Naccarelli G, et al. Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. The VIGOR CHF and VENTAK CHF investigators. Am J Cardiol 1999; 83: 120-3D. http://dx. doi. org/10. 1016/S0002-9149(98)01012-1.
128. Lozano I, Bocchiardo M, Achtelik M, Gaita F, Trappe HJ, Daoud E, et al. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias. Pacing Clin Electrophysiol 2000; 23: 1711-12. http://dx. doi. org/10. 1111/j. 1540-8159. 2000. tb07001. x.
129. US Food and Drug Administration. Summary of Safety and Effectiveness. Original PMA P010012. Washington, DC: US Food and Drug Administration; 2002.
130. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-38. http://dx. doi. org/10. 1056/NEJMoa0906431.
131. Moss AJ, Brown MW, Cannom DS, Daubert JP, Estes M, Foster E, et al. Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol 2005; 10: 34-43. http://dx. doi. org/10. 1111/j. 1542-474X. 2005. 00073. x.
132. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy. Circulation 2010; 122: 985-92. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 110. 955039.
133. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011; 124: 1527-36. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 110. 014324.
134. Goldenberg I, Hall WJ, Beck CA, Moss AJ, Barsheshet A, McNitt S, et al. Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol 2011; 58: 729-37. http://dx. doi. org/10. 1016/j. jacc. 2011. 04. 024.
135. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011; 57: 813-20. http://dx. doi. org/10. 1016/j. jacc. 2010. 06. 061.
136. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 2003; 289: 2685-94. http://dx. doi. org/10. 1001/jama. 289. 20. 2685.
137. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004; 110: 2864-8. http://dx. doi. org/10. 1161/01. CIR. 0000146336. 92331. D1.
138. Piccirillo G, Magri D, di Carlo S, De Laurentis T, Torrini A, Matera S, et al. Influence of cardiac-resynchronization therapy on heart rate and blood pressure variability: 1-year follow-up. Eur J Heart Fail 2006; 8: 716-22. http://dx. doi. org/10. 1016/j. ejheart. 2006. 01. 008.
139. Pinter A, Mangat I, Korley V, Connolly S, Connors S, Gardner M, et al. Assessment of resynchronization therapy on functional status and quality of life in patients requiring an implantable defibrillator. Pacing Clin Electrophysiol 2009; 32: 1509-19. http://dx. doi. org/10. 1111/j. 1540-8159. 2009. 02543. x.
140. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-95. http://dx. doi. org/10. 1056/NEJMoa1009540.
141. Tang AS, Wells GA, Arnold M, Connolly S, Hohnloser S, Nichol G, et al. Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design. Curr Opin Cardiol 2009; 24: 1-8. http://dx. doi. org/10. 1097/HCO. 0b013e32831bc63b.
142. Beshai JF, Grimm RA, Nagueh SF, Baker JH, Beau SL, Greenberg SM, et al. Cardiacresynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007; 357: 2461-71. http://dx. doi. org/10. 1056/NEJMoa0706695.
143. Beshai JF, Grimm R. The resynchronization therapy in narrow QRS study (RethinQ study): methods and protocol design. J Interv Card Electrophysiol 2007; 19: 149-55. [Erratum published in J Interv Card Electrophysiol 2008; 21: 69.] http://dx. doi. org/10. 1007/s10840-007-9156-3.
144. US Food and Drug Administration. Summary of Safety and Effectiveness Data. P030054. Washington, DC: US Food and Drug Administration; 2004.
145. US Food and Drug Administration. Summary of Safety and Effectiveness Data. P030054_S10. Washington, DC: US Food and Drug Administration; 2005.
146. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial investigators. N Engl J Med 1999; 341: 1882-90. [Erratum published in N Engl J Med 2000; 342: 1300.] http://dx. doi. org/10. 1056/NEJM199912163412503.
147. Lau EW, Griffith MJ, Pathmanathan RK, Ng GA, Clune MM, Cooper J, et al. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-Guided Interventions and Implantable Cardioverter-Defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death. Europace 2004; 6: 257-66. http://dx. doi. org/10. 1016/j. eupc. 2004. 03. 009.
148. Lee KL, Hafley G, Fisher JD, Gold MR, Prystowsky EN, Talajic M, et al. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation 2002; 106: 233-8. http://dx. doi. org/10. 1161/01. CIR. 0000021920. 73149. C3.
149. Wang K, Yamauchi K, Li P, Kato H, Kobayashi M, Kato K, et al. Cost-effectiveness of implantable cardioverter-defibrillators in Brugada syndrome treatment. J Med Syst 2008; 32: 51-7. http://dx. doi. org/10. 1007/s10916-007-9107-7.
150. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail 2012; 14: 628-34. http://dx. doi. org/10. 1093/eurjhf/hfs055.
151. Association of British Healthcare Industries. Implantable Cardioverter Defibrillators for the Treatment of Arrhythmias and Cardiac Resynchronisation Therapy for the Treatment of Heart Failure (Review of TA95 and TA120). London: ABHI; 2012.
152. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. CHE Discussion Paper 172. York: University of York, Centre for Health Economics; 1999.
153. Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess 2006; 10(27).
154. Al-Khatib SM, Anstrom KJ, Eisenstein EL, Peterson ED, Jollis JG, Mark DB, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 2005; 142: 593-600. http://dx. doi. org/10. 7326/0003-4819-142-8-200504190-00007.
155. Bertoldi EG, Rohde LE, Zimerman LI, Pimentel M, Polanczyk CA. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system. Int J Cardiol 2011; 163: 309-15. http://dx. doi. org/10. 1016/j. ijcard. 2011. 06. 046.
156. Caro JJ, Ward A, Deniz HB, O'Brien JA, Ehreth JL. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone. Value Health 2007; 10: 13-22. http://dx. doi. org/10. 1111/j. 1524-4733. 2006. 00140. x.
157. Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol 2006; 48: 112-21. http://dx. doi. org/10. 1016/j. jacc. 2006. 02. 051.
158. Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, et al. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes 2009; 2: 16-24. http://dx. doi. org/10. 1161/CIRCOUTCOMES. 108. 807123.
159. Chen L, Hay JW. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther 2004; 18: 161-70. http://dx. doi. org/10. 1023/B: CARD. 0000029034. 65769. f7.
160. Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace 2009; 11: 716-26. http://dx. doi. org/10. 1093/europace/eup068.
161. Deniz HB, Ward A, Jaime CJ, Alvarez P, Sadri H. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada. Curr Med Res Opin 2009; 25: 617-26. http://dx. doi. org/10. 1185/03007990802695037.
162. Feingold B, Arora G, Webber SA, Smith KJ. Cost-effectiveness of implantable cardioverterdefibrillators in children with dilated cardiomyopathy. J Card Fail 2010; 16: 734-41. http://dx. doi. org/10. 1016/j. cardfail. 2010. 04. 009.
163. Filion KB, Xie X, van der Avoort CJ, Dendukuri N, Brophy JM. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study. Int J Technol Assess Health Care 2009; 25: 151-60. http://dx. doi. org/10. 1017/S0266462309090205.
164. Gandjour A, Holler A, Dipl GO, Adarkwah CC. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II). Value Health 2011; 14: 812-17. http://dx. doi. org/10. 1016/j. jval. 2011. 02. 1180.
165. Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol 2005; 10(Suppl. 4): 83. http://dx. doi. org/10. 1111/j. 1542-474X. 2005. 00070. x.
166. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT Jr, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990; 81: 91-100. http://dx. doi. org/10. 1161/01. CIR. 81. 1. 91.
167. Kupersmith J, Hogan A, Guerrero P, Gardiner J, Mellits ED, Baumgardner R, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J 1995; 130: 507-15. http://dx. doi. org/10. 1016/0002-8703(95)90359-3.
168. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NA, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992; 19: 1323-34. http://dx. doi. org/10. 1016/0735-1097(92)90341-J.
169. Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002; 105: 2049-57. http://dx. doi. org/10. 1161/01. CIR. 0000015504. 57641. D0.
170. Mark DB, Nelson CL, Anstrom KJ, Al Khatib SM, Tsiatis AA, Cowper PA, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006; 114: 135-42. http://dx. doi. org/10. 1161/CIRCULATIONAHA. 105. 581884.
171. McGregor M, Chen J. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of the issues relevant to hospital decision making. Can J Cardiol 2004; 20: 1199-204.
172. Medical Services Advisory Committee. Implantable Cardioverter Defibrillators for Prevention of Sudden Cardiac Death. Canberra: Australian Government Department of Health and Ageing; 2006.
173. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Circulation 1998; 97: 2129-35. http://dx. doi. org/10. 1161/01. CIR. 97. 21. 2129.
174. Neyt M, Thiry N, Ramaekers D, Van Brabandt H. Cost effectiveness of implantable cardioverterdefibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy 2008; 6: 67-80. http://dx. doi. org/10. 2165/00148365-200806010-00006.
175. O'Brien BJ, Buxton MJ, Rushby JA. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis. Br Heart J 1992; 68: 241-5. http://dx. doi. org/10. 1136/hrt. 68. 8. 241.
176. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997; 126: 1-12. http://dx. doi. org/10. 7326/0003-4819-126-1-199701010-00001.
177. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 2002; 144: 440-8. http://dx. doi. org/10. 1067/mhj. 2002. 125501.
178. Ribeiro RA, Stella SF, Zimerman LI, Pimentel M, Rohde LE, Polanczyk CA. Cost-effectiveness of implantable cardioverter defibrillators in Brazil in the public and private sectors. Arq Bras Cardiol 2010; 95: 577-86. http://dx. doi. org/10. 1590/S0066-782X2010005000134.
179. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001; 135: 870-83. http://dx. doi. org/10. 7326/0003-4819-135-10-200111200-00007.
180. Sanders GD, Hlatky MA, Owens DK. Special report: cost-effectiveness of implantable cardioverter defibrillators in a MADIT-II population. Technol Eval Cent Assess Program Exec Summ 2004; 19: 1-22.
181. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353: 1471-80. http://dx. doi. org/10. 1056/NEJMsa051989.
182. Sanders GD, Kong MH, Al-Khatib SM, Peterson ED. Cost-effectiveness of implantable cardioverter defibrillators in patients ≥ 65 years of age. Am Heart J 2010; 160: 122-31. http://dx. doi. org/10. 1016/j. ahj. 2010. 04. 021.
183. Sheldon R, O'Brien BJ, Blackhouse G, Goeree R, Mitchell B, Klein G, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 2001; 104: 1622-6. http://dx. doi. org/10. 1161/hc3901. 096720.
184. Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and costeffectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. Am J Med 2002; 112: 519-27. http://dx. doi. org/10. 1016/S0002-9343(02)01078-1.
185. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J 2007; 154: 899-907. http://dx. doi. org/10. 1016/j. ahj. 2007. 06. 026.
186. Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47: 2310-18. http://dx. doi. org/10. 1016/j. jacc. 2006. 03. 032.
187. Banz K. Cardiac resynchronization therapy (CRT) in heart failure-a model to assess the economic value of this new medical technology. Value Health 2005; 8: 128-39. http://dx. doi. org/10. 1111/j. 1524-4733. 2005. 03092. x.
188. Callejo D, Guerra M, Hernandez-Madrid A, Blasco JA. Economic assessment of cardiac resynchronization therapy. Rev Esp Cardiol 2010; 63: 1235-43. http://dx. doi. org/10. 1016/S0300-8932(10)70293-1.
189. Calvert MJ, Freemantle N, Yao G, Cleland JG, Billingham L, Daubert JC, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005; 26: 2681-8. http://dx. doi. org/10. 1093/eurheartj/ehi662.
190. Caro JJ, Guo S, Ward A, Chalil S, Malik F, Leyva F. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK. Curr Med Res Opin 2006; 22: 1171-9. http://dx. doi. org/10. 1185/030079906X112516.
191. Blomstrom P, Ekman M, Lundqvist CB, Calvert MJ, Freemantle N, Lonnerholm S, et al. Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial. Eur J Heart Fail 2008; 10: 869-77. http://dx. doi. org/10. 1016/j. ejheart. 2008. 06. 018.
192. Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass DA, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2311-21. http://dx. doi. org/10. 1016/j. jacc. 2005. 08. 033.
193. Heerey A, Lauer M, Alsolaiman F, Czerr J, James K. Cost effectiveness of biventricular pacemakers in heart failure patients. Am J Cardiovasc Drugs 2006; 6: 129-37. http://dx. doi. org/10. 2165/00129784-200606020-00007.
194. McAlister F, Ezekowitz J, Wiebe N, Rowe B, Spooner C, Crumley E, et al. Cardiac Resynchronization Therapy for Congestive Heart Failure: Summary. AHRQ Evidence Report Summaries 106. Rockville, MD: Agency for Healthcare Research; 2004.
195. Medical Services Advisory Committee. Cardiac Resynchronisation Therapy for Severe Heart Failure. Canberra: Australian Government Department of Health and Ageing; 2006.
196. Neyt M, Stroobandt S, Obyn C, Camberlin C, Devriese S, De Laet C, et al. Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. BMJ Open 2011; 1: e000276. http://dx. doi. org/10. 1136/bmjopen-2011-000276.
197. Nichol G, Kaul P, Huszti E, Bridges JF. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 343-51. http://dx. doi. org/10. 7326/0003-4819-141-5-200409070-00102.
198. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28: 42-51. http://dx. doi. org/10. 1093/eurheartj/ehl382.
199. Aidelsburger P, Grabein K, Klauss V, Wasem J. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective. Clin Res Cardiol 2008; 97: 89-97. http://dx. doi. org/10. 1007/s00392-007-0586-9.
200. Poggio R, Augustovsky F, Caporale J, Irazola V, Miriuka S. Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina. Int J Technol Assess Health Care 2012; 28: 429-35. http://dx. doi. org/10. 1017/S0266462312000505.
201. Ribeiro RA, Stella SF, Camey SA, Zimerman LI, Pimentel M, Rohde LE, et al. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector. Value Health 2010; 13: 160-8. http://dx. doi. org/10. 1111/j. 1524-4733. 2009. 00608. x.
202. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001; 103: 1416-21. http://dx. doi. org/10. 1161/01. CIR. 103. 10. 1416.
203. Bond M, Mealing S, Anderson R, Dean J, Stein K, Taylor RS. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction? Int J Cardiol 2009; 137: 206-15. http://dx. doi. org/10. 1016/j. ijcard. 2008. 05. 073.
204. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026-33. http://dx. doi. org/10. 1016/S0735-1097(02)01895-8.
205. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780-7. http://dx. doi. org/10. 1053/euhj. 2002. 3232.
206. Garrigue S, Bordachar P, Reuter S, Jais P, Haissaguerre M, Clementy J. Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic atrial fibrillation: a prospective hemodynamic study. Card Electrophysiol Rev 2003; 7: 315-24. http://dx. doi. org/10. 1023/B: CEPR. 0000023167. 11038. 8f.
207. Leclerq C, Cazeau S, Lellouche D, et al. Upgrading from Right Ventricular Pacing to Biventricular Pacing in Previously Paced Patients with Advanced Heart Failure: a Randomized Controlled Study (the RD-CHF Trial). European Society of Cardiology Congress, Vienna, Austria, 30 August-3 September 2003.
208. Linde C, Gold M, Abraham WT, Daubert J-C. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure-The REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. American Heart Journal 2006; 151: 288-294. http://dx. doi. org/10. 1016/j. ahj. 2005. 03. 002.
209. Moss A. MADIT-CRT: the Multicentre Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy. Eur J Heart Fail 2009; 11: 1217-19.
210. Kirsch J, McGuire A. Establishing health state valuations for disease-specific states: an example from heart disease. Health Econ 2000; 9: 149-58. http://dx. doi. org/10. 1002/(SICI)1099-1050 (200003)9: 2<149:: AID-HEC501>3. 0. CO; 2-N.
211. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005; 7: 243-51. http://dx. doi. org/10. 1016/j. ejheart. 2005. 01. 012.
212. National Institute for Health and Care Excellence. Guide to the Single Technology Appraisal Process. London: NICE; 2009. URL: www. nice. org. uk/media/42D/B3/STAGuideLrFinal. pdf (accessed 23 January 2014).
213. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes 2006; 4: 89. http://dx. doi. org/10. 1186/1477-7525-4-89.
214. Gohler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, et al. Utility estimates for decision-analytic modeling in chronic heart failure-health states based on New York Heart Association classes and number of rehospitalizations. Value Health 2009; 12: 185-7. http://dx. doi. org/10. 1111/j. 1524-4733. 2008. 00425. x.
215. Groeneveld PW, Matta MA, Suh JJ, Yang F, Shea JA. Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era. Pacing Clin Electrophysiol 2007; 30: 463-71. http://dx. doi. org/10. 1111/j. 1540-8159. 2007. 00694. x.
216. Holland R, Brooksby I, Lenaghan E, Ashton K, Hay L, Smith R, et al. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. BMJ 2007; 334: 1098. http://dx. doi. org/10. 1136/bmj. 39164. 568183. AE.
217. Public Health England. Central Cardiac Audit Database (CCAD). URL: http://www. sepho. org. uk/viewResource. aspx?id=6584 (accessed April 2014).
218. Department of Health. NHS Reference Costs 2010-2011. URL: www. dh. gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_122803 (accessed 23 January 2014).
219. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 61, March 2011. London: BMA and RPS; 2011.
220. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
221. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003; 138: 445-52. http://dx. doi. org/10. 7326/0003-4819-138-6-200303180-00007.
222. Townsend N, Wickramasinghe K, Bhatnagar P, Smolina K, Nichols M, Leal J. Coronary Heart Disease Statistics: 2012 Edition. London: British Heart Foundation; 2012.
223. Curnis A, Caprari F, Mascioli G, Bontempi L, Scivales A, Bianchetti F, et al. Biventricular Cardiac Resynchronization in Moderate-to-Severe Heart Failure: Analysis of Hospital Costs and Clinical Effectiveness (Brescia Study). Milan: Springer-Verlag Italia; 2003.
224. Shahar E, Lee S, Kim J, Duval S, Barber C, Luepker RV. Hospitalized heart failure: rates and long-term mortality. J Card Fail 2004; 10: 374-9. http://dx. doi. org/10. 1016/j. cardfail. 2004. 02. 003.
225. Oxford Healthcare Associates. Access to Cardiac Care in the UK: A Report on Recent Trends, Variations in Access & Future Need. Oxford: British Cardiac Society and the British Heart Foundation; 2009. URL: www. bcs. com/documents/C1D_Access_to_Cardiac_Care_in_the_UK_-_UK_by_Country_&_English_SHA_-_FINAL2. pdf (accessed 23 January 2014).
226. UK Cardiothoracic Transplant Audit Steering Group. UK Cardiothoracic Transplant Audit, Annual Report. London: Clinical Effectiveness Unit, Royal College of Surgeons of England, and Statistics and Clinical Audit, NHS Blood and Transplant; 2011.
227. Hussey JC, Bond ZC, Collett D, Wallwork J. Long term patient survival for heart transplant recipients in the UK. URL: www. organdonation. nhs. uk/statistics/presentations/pdfs/bts_2004_long-term_pt_survival_%20heart. pdf (accessed 23 January 2014).
228. Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 2006; 42: 2867-75. http://dx. doi. org/10. 1016/j. ejca. 2006. 08. 010.
229. Department of Health. NHS UK Tariff 2012-13. URL: www. dh. gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_132654. 2012 (accessed 23 January 2014).
230. Huang Y, Wu W, Cao Y, Qu N. All cause mortality of cardiac resynchronization therapy with implantable cardioverter defibrillator: a meta-analysis of randomized controlled trials. Int J Cardiol 2010; 145: 413-17. http://dx. doi. org/10. 1016/j. ijcard. 2010. 05. 016.
231. Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011; 154: 401-12. http://dx. doi. org/10. 7326/0003-4819-154-6-201103150-00313.
232. Wells G, Parkash R, Healey JS, Talajic M, Arnold JM, Sullivan S, et al. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ 2011; 183: 421-9. http://dx. doi. org/10. 1503/cmaj. 101685.
233. Bertoldi EG, Polanczyk CA, Cunha V, Ziegelmann PK, Beck-da-Silva L, Rohde LE. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care? Journal of Card Fail 2011; 17: 860-6. http://dx. doi. org/10. 1016/j. cardfail. 2011. 06. 372.
234. Kron J, Herre J, Renfroe EG, Rizo-Patron C, Raitt M, Halperin B, et al. Lead-and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 2001; 141: 92-8. http://dx. doi. org/10. 1067/mhj. 2001. 111261.
235. Kron J. Clinical significance of device-related complications in clinical trials and implications for future trials: insights from the Antiarrhytmics Versus Implantable Defibrillators (AVID) trial. Card Electrophysiol Rev 2003; 7: 473-8. http://dx. doi. org/10. 1023/B: CEPR. 0000023163. 67758. b1.
236. Klein RC, Raitt MH, Wilkoff BL, Beckman KJ, Coromilas J, Wyse DG, et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Cardiovasc Electrophysiol 2003; 14: 940-8. http://dx. doi. org/10. 1046/j. 1540-8167. 2003. 01554. x.
237. Curtis AB, Cannom DS, Bigger JT Jr, DiMarco JP, Estes NA III, Steinman RC, et al. Baseline characteristics of patients in the Coronary Artery Bypass Graft (CABG) Patch trial. Am Heart J 1997; 134: 787-98. http://dx. doi. org/10. 1016/S0002-8703(97)80001-4.
238. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg. Pacing Clin Electrophysiol 1993; 16: 552-8. http://dx. doi. org/10. 1111/j. 1540-8159. 1993. tb01624. x.
239. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993; 72: 109-13F. http://dx. doi. org/10. 1016/0002-9149 (93)90973-G.
240. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994; 127: 1139-44. http://dx. doi. org/10. 1016/0002-8703(94)90101-5.
241. Foley PW, Patel K, Irwin N, Sanderson JE, Frenneaux MP, Smith RE, et al. Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. Heart 2011; 97: 1041-7. http://dx. doi. org/10. 1136/hrt. 2010. 208355.
242. Linde C, Gold M, Abraham WT, Daubert JC, REVERSE Study Group. Baseline characteristics of patients randomized in the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Congest Heart Fail 2008; 14: 66-74. http://dx. doi. org/10. 1111/j. 1751-7133. 2008. 07613. x.
243. Linde C, Abraham WT, Gold MR, St John SM, Ghio S, Daubert C, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52: 1834-43 http://dx. doi. org/10. 1016/j. jacc. 2008. 08. 027.
244. US Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED); 2005. URL: www. fda. gov/ohrms/dockets/dockets/05m0289/05m-0289-aav0001-03-SSED-vol1. pdf (accessed April 2014).